WEKO3
アイテム
{"_buckets": {"deposit": "5af26728-d8ac-4c09-a197-ce8fede3fbe9"}, "_deposit": {"created_by": 1, "id": "85109", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "85109"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00085109", "sets": ["1"]}, "author_link": ["1026134", "1026142", "1026143", "1026138", "1026129", "1026139", "1026144", "1026137", "1026131", "1026133", "1026145", "1026135", "1026136", "1026130", "1026141", "1026140", "1026132"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2022-02", "bibliographicIssueDateType": "Issued"}, "bibliographicPageEnd": "15", "bibliographicPageStart": "10", "bibliographicVolumeNumber": "108-109", "bibliographic_titles": [{"bibliographic_title": "Nuclear Medicine and Biology"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: [64Cu]Cu-diacethyl-bis(N4-methylthiosemicarbazone) ([64Cu]Cu-ATSM) is a radioactive hypoxia-targeting therapeutic agent, and the efficacy and safety of [64Cu]Cu-ATSM in the treatment of malignant brain tumors are evaluated in clinical trials. For the clinical application of [64Cu]Cu-ATSM, we determined a drug formulation incorporating a stabilizer against radiolysis and confirmed its radiochemical stability. This study aimed to identify trace chemical impurities derived from the degradation of ATSM contained in the [64Cu]Cu-ATSM investigational drug formulation and assess their potential hazards by quantitative structure–activity relationship (QSAR) assessment.\nMethods: We hypothesized that the chemical impurities contained in the [64Cu]Cu-ATSM formulation were derived from the degradation of ATSM. Therefore, we first identified the degradants of ATSM using LC-MS/MS. ATSM was dissolved with the drug formulation of [64Cu]Cu-ATSM, except for 64Cu, and analyzed by LC-MS/MS at 0 and 48 h after sample preparation. Subsequently, the chemical impurities contained in the [64Cu]Cu-ATSM formulation were measured at 0, 5, and 24 h after preparation by HPLC, and the results were compared to the degradants of ATSM. The potential hazards of the chemical impurities contained in the [64Cu]Cu-ATSM formulation were assessed using the QSAR Toolbox (ver. 4.3). \nResults: Six ATSM degradants were detected and identified by LC-MS/MS analysis, indicating that the functional groups around the nitrogen and sulfur atoms of ATSM were affected. The same peaks were detected as trace chemical impurities in the [64Cu]Cu-ATSM formulation at 24 h, while no apparent peaks were detected at 0 and 5 h. The estimated LD50 values of these chemical impurities showed 4.31 mg/kg or more by QSAR assessment. In contrast, the estimated amount of each chemical impurity exposed to patients was 31.8 ng/kg or less per dose. The smallest margin between the amount of chemical impurities and smallest estimated LD50 value of the corresponding impurity was a ratio of approximately 1:700,000.\nConclusions: We identified trace chemical impurities derived from ATSM in the [64Cu]Cu-ATSM formulation. This suggests that the potential risk of the systemic exposure of patients to these chemical impurities is substantially low.", "subitem_description_type": "Abstract"}]}, "item_8_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Elsevier "}]}, "item_8_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1016/j.nucmedbio.2022.02.001", "subitem_relation_type_select": "DOI"}}]}, "item_8_relation_17": {"attribute_name": "関連サイト", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.sciencedirect.com/science/article/pii/S0969805122000129", "subitem_relation_type_select": "URI"}}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0969-8051", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Chika, Igarashi"}], "nameIdentifiers": [{"nameIdentifier": "1026129", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hiroki, Matsumoto"}], "nameIdentifiers": [{"nameIdentifier": "1026130", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masashi, Takahashi"}], "nameIdentifiers": [{"nameIdentifier": "1026131", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukiko, Hihara"}], "nameIdentifiers": [{"nameIdentifier": "1026132", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tomoko, Tachibana"}], "nameIdentifiers": [{"nameIdentifier": "1026133", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Ming-Rong"}], "nameIdentifiers": [{"nameIdentifier": "1026134", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hiroaki, Kurihara"}], "nameIdentifiers": [{"nameIdentifier": "1026135", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tatsuya, Higashi"}], "nameIdentifiers": [{"nameIdentifier": "1026136", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yukie, Yoshii"}], "nameIdentifiers": [{"nameIdentifier": "1026137", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Chika, Igarashi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026138", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hiroki, Matsumoto", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026139", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masashi, Takahashi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026140", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukiko, Hihara", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026141", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tomoko, Tachibana", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026142", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Ming-Rong", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026143", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tatsuya, Higashi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026144", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yukie, Yoshii", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026145", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Identification and quantitative structure–activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [64Cu]Cu-ATSM", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Identification and quantitative structure–activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [64Cu]Cu-ATSM"}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/85109", "pubdate": {"attribute_name": "公開日", "attribute_value": "2021-12-03"}, "publish_date": "2021-12-03", "publish_status": "0", "recid": "85109", "relation": {}, "relation_version_is_last": true, "title": ["Identification and quantitative structure–activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [64Cu]Cu-ATSM"], "weko_shared_id": -1}
Identification and quantitative structure–activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [64Cu]Cu-ATSM
https://repo.qst.go.jp/records/85109
https://repo.qst.go.jp/records/8510934a9b802-2e7a-4b62-a6ef-9ca7dfce5696
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-12-03 | |||||
タイトル | ||||||
タイトル | Identification and quantitative structure–activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [64Cu]Cu-ATSM | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Chika, Igarashi
× Chika, Igarashi× Hiroki, Matsumoto× Masashi, Takahashi× Fukiko, Hihara× Tomoko, Tachibana× Zhang, Ming-Rong× Hiroaki, Kurihara× Tatsuya, Higashi× Yukie, Yoshii× Chika, Igarashi× Hiroki, Matsumoto× Masashi, Takahashi× Fukiko, Hihara× Tomoko, Tachibana× Zhang, Ming-Rong× Tatsuya, Higashi× Yukie, Yoshii |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background: [64Cu]Cu-diacethyl-bis(N4-methylthiosemicarbazone) ([64Cu]Cu-ATSM) is a radioactive hypoxia-targeting therapeutic agent, and the efficacy and safety of [64Cu]Cu-ATSM in the treatment of malignant brain tumors are evaluated in clinical trials. For the clinical application of [64Cu]Cu-ATSM, we determined a drug formulation incorporating a stabilizer against radiolysis and confirmed its radiochemical stability. This study aimed to identify trace chemical impurities derived from the degradation of ATSM contained in the [64Cu]Cu-ATSM investigational drug formulation and assess their potential hazards by quantitative structure–activity relationship (QSAR) assessment. Methods: We hypothesized that the chemical impurities contained in the [64Cu]Cu-ATSM formulation were derived from the degradation of ATSM. Therefore, we first identified the degradants of ATSM using LC-MS/MS. ATSM was dissolved with the drug formulation of [64Cu]Cu-ATSM, except for 64Cu, and analyzed by LC-MS/MS at 0 and 48 h after sample preparation. Subsequently, the chemical impurities contained in the [64Cu]Cu-ATSM formulation were measured at 0, 5, and 24 h after preparation by HPLC, and the results were compared to the degradants of ATSM. The potential hazards of the chemical impurities contained in the [64Cu]Cu-ATSM formulation were assessed using the QSAR Toolbox (ver. 4.3). Results: Six ATSM degradants were detected and identified by LC-MS/MS analysis, indicating that the functional groups around the nitrogen and sulfur atoms of ATSM were affected. The same peaks were detected as trace chemical impurities in the [64Cu]Cu-ATSM formulation at 24 h, while no apparent peaks were detected at 0 and 5 h. The estimated LD50 values of these chemical impurities showed 4.31 mg/kg or more by QSAR assessment. In contrast, the estimated amount of each chemical impurity exposed to patients was 31.8 ng/kg or less per dose. The smallest margin between the amount of chemical impurities and smallest estimated LD50 value of the corresponding impurity was a ratio of approximately 1:700,000. Conclusions: We identified trace chemical impurities derived from ATSM in the [64Cu]Cu-ATSM formulation. This suggests that the potential risk of the systemic exposure of patients to these chemical impurities is substantially low. |
|||||
書誌情報 |
Nuclear Medicine and Biology 巻 108-109, p. 10-15, 発行日 2022-02 |
|||||
出版者 | ||||||
出版者 | Elsevier | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0969-8051 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1016/j.nucmedbio.2022.02.001 | |||||
関連サイト | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://www.sciencedirect.com/science/article/pii/S0969805122000129 |